|Generic Name||Brand Name|
Alemtuzumab is given intravenously or as a shot under the skin.
Alemtuzumab is a monoclonal antibody that attaches itself to a protein called CD52. This protein is found on the surface of some cancer cells, including most chronic lymphocytic leukemia (CLL) cells. It helps your immune system see the cancer cell as something that needs to be destroyed.
Alemtuzumab may be used by itself or in combination with other drugs to treat chronic lymphocytic leukemia (CLL). Alemtuzumab is sometimes used in clinical trials to treat other types of leukemia.
For people who have CLL and who have not improved with other chemotherapy drugs such as cyclophosphamide, fludarabine, or rituximab (or a combination of these), alemtuzumab can be an effective treatment.
Common side effects include:
See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)
Your doctor may give you antibiotics to prevent infections for a certain period of time after your treatment.
Alemtuzumab can cause birth defects. Do not use this drug if you are pregnant or wish to become pregnant or to father a child while you are taking it.
Do not use alemtuzumab if you are breast-feeding. The drug can pass into your breast milk.
Alemtuzumab can interact with many other drugs. Be sure your doctor knows what prescription and over-the-counter drugs you are taking.
Use alemtuzumab with caution if you have heart disease. The drug may make existing heart problems worse.
This drug has been studied for use only in adults. Its safety and effectiveness have not been established in children.
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information.